delivery modes, they must meet the same standards as the Phase III trials conducted for initial approval.

REFERENCES

Baru, J. S., D. A. Bloom, K. Muraszko, and C. E. Koop. 2001. John Holter’s shunt. Journal of the American College of Surgeons 192(1):79-85.

Borie, D. C., J. J. O’Shea, and P. S. Changelian. 2004. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends in Molecular Medicine 10(11):532-541.

Changelian, P. S., D. Moshinsky, C. F. Kuhn, M. E. Flanagan, M. J. Munchhof, T. M. Harris, J. L. Doty, et al. 2008. The specificity of JAK3 kinase inhibitors. Blood 111(4):2155-2157.

IOM (Institute of Medicine). 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies. Washington, DC: The National Academies Press.

Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298(5600):1912-1934.

Russell, S. M., N. Tayebi, H. Nakajima, M. C. Riedy, J. L. Roberts, M. J. Aman, T. S. Migone, et al. 1995. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270(5237):797-800.

Stanczyk, J., C. Ospelt, and S. Gay. 2008. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Current Opinion in Rheumatology 20(3):257-262.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement